AIMDiV: Accessing Innovative Mental Health Services for Depression in Vietnam

Sponsor
Simon Fraser University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05783531
Collaborator
Grand Challenges Canada (Other), Ministry of Labour, Invalids and Social Affairs (MOLISA): Vietnam (Other)
336
2
36

Study Details

Study Description

Brief Summary

This stepped wedge, randomized controlled trial (RCT) will test the effectiveness of a digital mental health intervention (VMood) adapted from an evidence-based in-person intervention. The in-person intervention is based on principles of Cognitive Behavioural Therapy and uses a supported self-management approach consisting of a patient skills workbook and supportive coaching by a non-specialist provider. It was developed in Canada and shown to be effective in the Vietnamese context in a previous RCT conducted by the research team. The digital adaptation (VMood) is delivered via a Smartphone app the research team developed in Vietnam, in close collaboration with the Institute of Population, Health and Development (PHAD) in Vietnam.

The digital intervention will be delivered at the community level in 8 Vietnamese provinces, with remote coaching provided via the app by social workers. The primary outcome measure for the study is the Patient Health Questionnaire (PHQ-9), which screens for depression caseness. The investigators will also include the Generalized Anxiety Disorder(GAD-7) measure, as symptoms of anxiety commonly co-occur with depression. Secondary outcome measures will include the WHO Quality of Life-Brief (WHOQUAL-BREV), FAST Alcohol Screening Test (FAST), the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) adapted to assess tobacco use only. The investigators will also conduct a cost-effectiveness analysis (CEA) using the 5-level EQ-5D (EQ-5D-5L), the Health Economic Assessment (HEA) adapted for the Vietnamese health context, and Work Productivity and Activity Impairment Questionnaire: Depression (WPAID:D). Finally, the System Usability Scale (SUS) will be used to assess VMood usability.

Condition or Disease Intervention/Treatment Phase
  • Other: VMood
  • Other: Enhanced treatment as usual
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
336 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Stepped-wedge cluster randomizedStepped-wedge cluster randomized
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
AIMDiV: Accessing Innovative Mental Health Services for Depression in Vietnam
Anticipated Study Start Date :
Mar 31, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Mar 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

This arm will receive the VMood digital mental health intervention. This consists of bibliotherapy that is delivered via a smartphone app, with coaching support provided by social workers for a duration of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.

Other: VMood
VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.

Other: Control

This arm will receive enhanced treatment as usual, which consists of regular care as provided by primary care centres and a brief introduction video about depression via the app. The control arm will receive the intervention after the intervention arm has completed the intervention period.

Other: Enhanced treatment as usual
Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.

Outcome Measures

Primary Outcome Measures

  1. Patient Health Questionnaire (PHQ-9) - change in depression scores [Monthly from baseline until three months, with a follow-up at six months]

    A brief (9-item) measure for diagnosing and measuring severity of depression

  2. Generalized Anxiety Disorder (GAD-7) - change in anxiety scores [Monthly from baseline until three months, with a follow-up at six months]

    A brief (7-item) measure for assessing generalized anxiety disorder

Secondary Outcome Measures

  1. WHO Quality of Life- Brief (WHOQOL-BREV) [Three months, with a follow up at six months]

    To measure the effect of the intervention on quality of life

  2. Fast Alcohol Screening Test (FAST) [Three months, with a follow up at six months]

    To measure changes in the use of alcohol products

  3. Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) - Adapted [Three months, with a follow up at six months]

    To measure changes in the use of tobacco products

Other Outcome Measures

  1. EQ-5D-5L [Three months, with a follow up at six months]

    For cost-effectiveness analysis; to estimate health-related quality of life

  2. Health Economic Assessment (HEA) - Adapted [Three months, with a follow up at six months]

    For cost-effectiveness analysis; to estimate costs attributable to health resource utilization

  3. Work Productivity and Activity Impairment Questionnaire: Depression (WPAID:D) [Three months, with a follow up at six months]

    For cost-effectiveness analysis; to measure indirect costs attributable to potential productivity gains

  4. System Usability Scale (SUS) [Three months, with a follow up at six months]

    To assess the usability of the VMood app. The System Usability Scale (SUS) is an industry standard, validated 10-item Likert-type scale with five response options for measuring usability with 0 (strongly disagree) to 4 (strongly agree). Item scores are summed and the total is multiplied by 2.5. The composite score (between 0 and 100) provides an indicator of perceived usability - a higher score means better perceived ease of use. Research shows a score >68 is considered above average. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Score of >4 on PHQ-9 indicating depression caseness

  • consent to participate and complete all measures

Exclusion Criteria:
  • Cognitive disturbance

  • Psychotic symptoms

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Simon Fraser University
  • Grand Challenges Canada
  • Ministry of Labour, Invalids and Social Affairs (MOLISA): Vietnam

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
John O'Neil, Professor, Simon Fraser University
ClinicalTrials.gov Identifier:
NCT05783531
Other Study ID Numbers:
  • SFU ORS 26172
  • R-TTS-2205-52454
First Posted:
Mar 24, 2023
Last Update Posted:
Mar 24, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 24, 2023